NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

短腸症候群市場調查報告:醫藥品分類-2025年為止的預測-COVID-19累積的影響

Short Bowel Syndrome Market Research Report by Drug Class (GLP-2, Glutamine, and Growth Hormone), by Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2026 - Cumulative Impact of COVID-19

出版商 360iResearch LLP 商品編碼 1006218
出版日期 內容資訊 英文 186 Pages
商品交期: 最快1-2個工作天內
價格
短腸症候群市場調查報告:醫藥品分類-2025年為止的預測-COVID-19累積的影響 Short Bowel Syndrome Market Research Report by Drug Class (GLP-2, Glutamine, and Growth Hormone), by Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2026 - Cumulative Impact of COVID-19
出版日期: 2021年06月01日內容資訊: 英文 186 Pages
簡介

全球短腸症候群的市場規模預測將從2020年的8億6,406萬美元,擴大到2025年末的20億556萬美元。

COVID-19是前所未有的全球性公共衛生突發事件,已影響到每個行業。這種長期影響預計將在預測期內影響行業增長。我們正在進行的研究正在擴大我們的研究範圍,以確保我們窮究潛在的COVID-19問題和未來路徑。該報告考慮了消費者行為和需求的變化,購買方式,供應鏈的重新改道,當前市場趨勢以及政府的重要介入等因素,提供有關COVID-19的洞察,分析,與預測。

本報告提供短腸症候群市場相關調查,提供市場概要,以及醫藥品分類,各地區的趨勢,COVID-19累積的影響,及加入此市場的主要企業簡介等資訊。

目錄

第1章 序文

  • 調查的目的
  • 市場區隔和範圍
  • 調查涵蓋年份
  • 貨幣和價格
  • 語言
  • 限制事項
  • 利害關係者

第2章 調查手法

  • 調查流程
    • 定義:調查目的
    • 決策:調查設計
    • 準備:調查設備
    • 收集:資料來源
    • 分析:資料的解釋
    • 制定:資料檢驗
    • 公開:調查報告
    • 重複:報告的更新
  • 調查的實行
    • 開始:調查流程
    • 計劃:調查計劃作成
    • 實行:調查實施
    • 檢驗:發現與分析
    • 出版物:調查報告
  • 調查成果

第3章 摘要整理

  • 簡介
  • 市場預測
  • 各醫藥品分類預測
  • 各地區預測
  • 其他競爭公司預測

第4章 市場概要

  • 簡介
  • COVID-19累積的影響

第5章 市場洞察

  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 課題
  • 波特五力分析
    • 新加入廠商業者的威脅
    • 替代品的威脅
    • 客戶談判力
    • 供給企業談判力
    • 產業的競爭

第6章 短腸症候群市場,各醫藥品分類

  • GLP-2
  • 麩醯胺酸
  • 生長激素

第7章 南北美洲的短腸症候群市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第8章 亞太地區的短腸症候群市場

  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 韓國
  • 泰國

第9章 歐洲,中東·非洲的短腸症候群市場

  • 法國
  • 德國
  • 義大利
  • 荷蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 阿拉伯聯合大公國
  • 英國

第10章 競爭情形

  • FPNV定位矩陣
    • 象限
    • 事業策略
    • 產品的滿意度
  • 市場排行榜分析
  • 市場佔有率分析
  • 其他競爭公司的SWOT分析
  • 競爭模式
    • 合併和收購
    • 契約,合作,及夥伴關係
    • 新產品的銷售與強化
    • 投資與資金籌措
    • 獎,獎勵,擴大

第11章 企業的實用性簡介

  • 9 Meters Biopharma, Inc.
  • Adocia SAS
  • Ardelyx Inc
  • AstraZeneca PLC
  • Emmaus Life Sciences, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Mylan N.V.
  • Naia Pharmaceuticals, Inc.
  • Nestle S.A.,
  • Novartis International AG
  • Nutrinia Ltd
  • OPKO Health Inc.
  • OxThera AB
  • Pfizer Inc.
  • PhaseBio Pharmaceuticals Inc.
  • Sancilio & Company Inc
  • Shire PLC
  • Swedish Orphan Biovitrum AB
  • Teva Pharmaceutical Industries Ltd
  • VectivBio AG
  • Zealand Pharma A/S

第12章 附錄

  • 討論指南
  • 許可證和價格
  • 聯絡處詳細內容

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MRR-0309FBC5113F

The Global Short Bowel Syndrome Market size was estimated at USD 864.06 Million in 2020 and expected to reach USD 1,026.86 Million in 2021, at a Compound Annual Growth Rate (CAGR) 19.18% to reach USD 2,476.11 Million by 2026.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Short Bowel Syndrome to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Drug Class, the Short Bowel Syndrome Market was studied across GLP-2, Glutamine, and Growth Hormone.

Based on Geography, the Short Bowel Syndrome Market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Short Bowel Syndrome Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Short Bowel Syndrome Market, including 9 Meters Biopharma, Inc., Adocia SAS, Ardelyx Inc, AstraZeneca PLC, Emmaus Life Sciences, Inc., Johnson & Johnson Services, Inc., Merck KGaA, Mylan N.V., Naia Pharmaceuticals, Inc., Nestle S.A.,, Novartis International AG, Nutrinia Ltd, OPKO Health Inc., OxThera AB, Pfizer Inc., PhaseBio Pharmaceuticals Inc., Sancilio & Company Inc, Shire PLC, Swedish Orphan Biovitrum AB, Teva Pharmaceutical Industries Ltd, VectivBio AG, and Zealand Pharma A/S.

The report provides insights on the following pointers:

  • 1. Market Penetration: Provides comprehensive information on the market offered by the key players
  • 2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
  • 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
  • 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
  • 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

  • 1. What is the market size and forecast of the Global Short Bowel Syndrome Market?
  • 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Short Bowel Syndrome Market during the forecast period?
  • 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Short Bowel Syndrome Market?
  • 4. What is the competitive strategic window for opportunities in the Global Short Bowel Syndrome Market?
  • 5. What are the technology trends and regulatory frameworks in the Global Short Bowel Syndrome Market?
  • 6. What is the market share of the leading vendors in the Global Short Bowel Syndrome Market?
  • 7. What modes and strategic moves are considered suitable for entering the Global Short Bowel Syndrome Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

  • 3.1. Introduction
  • 3.2. Market Outlook
  • 3.3. Drug Class Outlook
  • 3.4. Geography Outlook
  • 3.5. Competitor Outlook

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increased prevalence of short bowel syndrome and awareness programs by non-profit organizations
      • 5.1.1.2. Rising efforts in the launch of effective treatments
      • 5.1.1.3. Awareness Programs by Non-Profit Organizations
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of approved treatment options
      • 5.1.2.2. Lethal adverse complications like colonic cancer, polyps along with common side effects associated with the medication
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of short bowel syndrome drugs is at a nascent stage
      • 5.1.3.2. Public-private partnerships are encouraging pharmaceutical companies to develop new orphan drugs for short bowel syndrome
    • 5.1.4. Challenges
      • 5.1.4.1. Awareness among physicians
  • 5.2. Cumulative Impact of COVID-19
  • 5.3. Porters Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry

6. Short Bowel Syndrome Market, by Drug Class

  • 6.1. Introduction
  • 6.2. GLP-2
  • 6.3. Glutamine
  • 6.4. Growth Hormone

7. Americas Short Bowel Syndrome Market

  • 7.1. Introduction
  • 7.2. Argentina
  • 7.3. Brazil
  • 7.4. Canada
  • 7.5. Mexico
  • 7.6. United States
    • 7.6.1. California
    • 7.6.2. Florida
    • 7.6.3. Illinois
    • 7.6.4. New York
    • 7.6.5. Ohio
    • 7.6.6. Pennsylvania
    • 7.6.7. Texas

8. Asia-Pacific Short Bowel Syndrome Market

  • 8.1. Introduction
  • 8.2. China
  • 8.3. India
  • 8.4. Indonesia
  • 8.5. Japan
  • 8.6. Malaysia
  • 8.7. Philippines
  • 8.8. South Korea
  • 8.9. Thailand

9. Europe, Middle East & Africa Short Bowel Syndrome Market

  • 9.1. Introduction
  • 9.2. France
  • 9.3. Germany
  • 9.4. Italy
  • 9.5. Netherlands
  • 9.6. Qatar
  • 9.7. Russia
  • 9.8. Saudi Arabia
  • 9.9. South Africa
  • 9.10. Spain
  • 9.11. United Arab Emirates
  • 9.12. United Kingdom

10. Competitive Landscape

  • 10.1. FPNV Positioning Matrix
    • 10.1.1. Quadrants
    • 10.1.2. Business Strategy
    • 10.1.3. Product Satisfaction
  • 10.2. Market Ranking Analysis
  • 10.3. Market Share Analysis, By Quadrant
  • 10.4. Market Share Analysis, By Company
  • 10.5. Competitive Scenario
    • 10.5.1. Merger & Acquisition
    • 10.5.2. Agreement, Collaboration, & Partnership
    • 10.5.3. New Product Launch & Enhancement
    • 10.5.4. Investment & Funding
    • 10.5.5. Award, Recognition, & Expansion

11. Company Usability Profiles

  • 11.1. 9 Meters Biopharma, Inc.
  • 11.2. Adocia SAS
  • 11.3. Ardelyx Inc
  • 11.4. AstraZeneca PLC
  • 11.5. Emmaus Life Sciences, Inc.
  • 11.6. Johnson & Johnson Services, Inc.
  • 11.7. Merck KGaA
  • 11.8. Mylan N.V.
  • 11.9. Naia Pharmaceuticals, Inc.
  • 11.10. Nestle S.A.,
  • 11.11. Novartis International AG
  • 11.12. Nutrinia Ltd
  • 11.13. OPKO Health Inc.
  • 11.14. OxThera AB
  • 11.15. Pfizer Inc.
  • 11.16. PhaseBio Pharmaceuticals Inc.
  • 11.17. Sancilio & Company Inc
  • 11.18. Shire PLC
  • 11.19. Swedish Orphan Biovitrum AB
  • 11.20. Teva Pharmaceutical Industries Ltd
  • 11.21. VectivBio AG
  • 11.22. Zealand Pharma A/S

12. Appendix

  • 12.1. Discussion Guide
  • 12.2. License & Pricing
  • 12.3. Contact Details

LIST OF FIGURES

  • FIGURE 1. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, 2020 VS 2026 (USD MILLION)
  • FIGURE 2. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2020 (USD MILLION)
  • FIGURE 3. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
  • FIGURE 4. GLOBAL SHORT BOWEL SYNDROME MARKET: MARKET DYNAMICS
  • FIGURE 5. GLOBAL SHORT BOWEL SYNDROME MARKET: PORTERS FIVE FORCES ANALYSIS
  • FIGURE 6. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2020 VS 2026 (%)
  • FIGURE 7. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2020 VS 2026 (USD MILLION)
  • FIGURE 8. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2026
  • FIGURE 9. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GLP-2, 2018-2026 (USD MILLION)
  • FIGURE 10. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GLP-2, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 11. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GLUTAMINE, 2018-2026 (USD MILLION)
  • FIGURE 12. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GLUTAMINE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 13. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GROWTH HORMONE, 2018-2026 (USD MILLION)
  • FIGURE 14. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GROWTH HORMONE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 15. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 16. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 17. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 18. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 19. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 20. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 21. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 22. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 23. CALIFORNIA SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 24. FLORIDA SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 25. ILLINOIS SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 26. NEW YORK SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 27. OHIO SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 28. PENNSYLVANIA SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 29. TEXAS SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 30. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 31. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 32. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 33. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 34. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 35. INDONESIA SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 36. JAPAN SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 37. MALAYSIA SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 38. PHILIPPINES SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 39. SOUTH KOREA SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 40. THAILAND SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 41. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 42. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 43. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 44. FRANCE SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 45. GERMANY SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 46. ITALY SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 47. NETHERLANDS SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 48. QATAR SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 49. RUSSIA SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 50. SAUDI ARABIA SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 51. SOUTH AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 52. SPAIN SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 53. UNITED ARAB EMIRATES SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 54. UNITED KINGDOM SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 55. GLOBAL SHORT BOWEL SYNDROME MARKET: FPNV POSITIONING MATRIX
  • FIGURE 56. GLOBAL SHORT BOWEL SYNDROME MARKET: SHARE, BY QUADRANT, 2020
  • FIGURE 57. GLOBAL SHORT BOWEL SYNDROME MARKET: SHARE, BY COMPANY, 2020
  • FIGURE 58. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL SHORT BOWEL SYNDROME MARKET, BY TYPE

LIST OF TABLES

  • TABLE 1. GLOBAL SHORT BOWEL SYNDROME MARKET: MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
  • TABLE 3. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 4. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GLP-2, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 5. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GLUTAMINE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 6. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GROWTH HORMONE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 7. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 8. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 9. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 10. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 11. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 12. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 13. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 14. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 15. CALIFORNIA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 16. FLORIDA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 17. ILLINOIS SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 18. NEW YORK SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 19. OHIO SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 20. PENNSYLVANIA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 21. TEXAS SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 22. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 23. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 24. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 25. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 26. INDONESIA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 27. JAPAN SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 28. MALAYSIA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 29. PHILIPPINES SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 30. SOUTH KOREA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 31. THAILAND SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 32. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 33. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 34. FRANCE SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 35. GERMANY SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 36. ITALY SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 37. NETHERLANDS SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 38. QATAR SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 39. RUSSIA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 40. SAUDI ARABIA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 41. SOUTH AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 42. SPAIN SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 43. UNITED ARAB EMIRATES SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 44. UNITED KINGDOM SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 45. GLOBAL SHORT BOWEL SYNDROME MARKET: SCORES
  • TABLE 46. GLOBAL SHORT BOWEL SYNDROME MARKET: BUSINESS STRATEGY
  • TABLE 47. GLOBAL SHORT BOWEL SYNDROME MARKET: PRODUCT SATISFACTION
  • TABLE 48. GLOBAL SHORT BOWEL SYNDROME MARKET: RANKING
  • TABLE 49. GLOBAL SHORT BOWEL SYNDROME MARKET: SHARE, BY QUADRANT, 2020
  • TABLE 50. GLOBAL SHORT BOWEL SYNDROME MARKET: SHARE, BY COMPANY, 2020
  • TABLE 51. GLOBAL SHORT BOWEL SYNDROME MARKET: MERGER & ACQUISITION
  • TABLE 52. GLOBAL SHORT BOWEL SYNDROME MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
  • TABLE 53. GLOBAL SHORT BOWEL SYNDROME MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  • TABLE 54. GLOBAL SHORT BOWEL SYNDROME MARKET: INVESTMENT & FUNDING
  • TABLE 55. GLOBAL SHORT BOWEL SYNDROME MARKET: AWARD, RECOGNITION, & EXPANSION
  • TABLE 56. GLOBAL SHORT BOWEL SYNDROME MARKET: LICENSE & PRICING
  • TABLE 57. GLOBAL SHORT BOWEL SYNDROME MARKET: CONTACT DETAILS